These are top 10 stocks traded on the Robinhood UK platform in July
IRVING, Texas - McKesson Corporation (NYSE: MCK), a global leader in healthcare services, has announced the completion of its acquisition of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), which was established by Florida Cancer Specialists & Research Institute, LLC (FCS). The transaction, valued at approximately $2.49 billion, aims to enhance community-based oncology care.
Florida Cancer Specialists, a practice with more than 250 physicians and 280 advanced practice providers across nearly 100 locations in Florida, retains a 30% interest and remains independently owned. FCS has also joined The US Oncology Network, a part of McKesson dedicated to improving local and affordable cancer care and patient outcomes. McKesson’s strong market position is reflected in its consistent dividend payments, which it has maintained for 32 consecutive years, demonstrating long-term financial stability.
This strategic acquisition is a part of McKesson’s broader commitment to advancing health outcomes for patients by partnering with various stakeholders in the healthcare industry, including biopharma companies, care providers, and governments.
McKesson’s Oncology and Specialty Solutions division is at the forefront of addressing the complexities in cancer care by providing research, insights, technologies, and services. Their efforts include facilitating patient participation in clinical trials through a joint venture with Sarah Cannon Research Institute, and advancing specialty care with The US Oncology Network and McKesson Provider Solutions.
Ontada, another McKesson business, is focused on generating real-world data and evidence, along with providing clinical education and provider technology to enhance cancer care. As one of the largest distributors of oncology and specialty medicines, McKesson plays a critical role in ensuring that these medications reach patients.
The company cautions that statements regarding the acquisition’s expected outcomes involve risks and uncertainties that could cause actual results to differ materially. Investors are encouraged to consider the risk factors outlined in McKesson’s most recent Form 10-K filing with the Securities and Exchange Commission. For deeper insights into McKesson’s valuation and growth prospects, InvestingPro subscribers can access comprehensive analysis, including 12+ additional ProTips and detailed financial metrics. The stock currently trades near its 52-week high, with analysts maintaining positive outlook projections for the coming year.
The information in this article is based on a press release statement from McKesson Corporation.
In other recent news, McKesson Corporation has reported a strong financial performance for its fiscal fourth quarter, with earnings per share (EPS) surpassing consensus estimates by 3%. The company has also provided an EPS guidance for fiscal year 2026 that exceeds current analyst expectations, maintaining a long-term EPS growth outlook of 12%-14%. Jefferies analyst Rob Dickerson responded to these developments by raising McKesson’s stock target to $800 and maintaining a Buy rating, citing the company’s robust earnings and appealing valuation. Despite this positive earnings report, McKesson’s Q3 2025 revenue fell short of forecasts, coming in at $90.82 billion against a forecast of $93.48 billion, which led to a 4.45% decline in the stock during aftermarket trading.
McKesson’s strategic acquisitions, including controlling interests in Prism Vision and pending acquisitions in CORE Ventures, have bolstered its position in the healthcare services sector. The company has announced plans to separate its Medical Surgical segment into an independent entity to enhance focus and operational efficiency. Looking ahead, McKesson projects revenue growth of 11% to 15% for fiscal 2026, with an anticipated EPS range of $36.05 to $37.55. These recent developments highlight McKesson’s continued efforts to strengthen its financial performance and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.